MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-20-2026
AbbVie DPO Ratio 2011-2026 | ABBV
Annual DPO Ratio AbbVie
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 65.5 | 71.6 | 59.2 | 61 | 54 | 44.2 | 71.2 | 73.1 | 76.4 | 88 | 130 | 72.7 | 74.3 | 45 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 130 | 44.2 | 70.4 |
Quarterly DPO Ratio AbbVie
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | 32.5 | - | - | - | 24.6 | - | - | - | 34.1 | - | - | - | 41.6 | - | - | - | 34.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 41.6 | 24.6 | 33.6 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Anika Therapeutics
ANIK
|
54.4 | $ 14.93 | 0.88 % | $ 219 M |  USA |
 |
Aptorum Group Limited
APM
|
405 | $ 0.93 | 0.51 % | $ 5.07 M |  China |
 |
Aquestive Therapeutics
AQST
|
395 | $ 4.14 | 0.36 % | $ 443 M | USA |
 |
Ardelyx
ARDX
|
163 | $ 6.06 | 1.94 % | $ 1.46 B | USA |
 |
Arcutis Biotherapeutics
ARQT
|
133 | $ 23.93 | 1.27 % | $ 3.04 B | USA |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
Atossa Therapeutics
ATOS
|
2.25 K | $ 5.19 | -3.36 % | $ 44.7 M | USA |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aurinia Pharmaceuticals
AUPH
|
47.5 | $ 16.05 | 2.79 % | $ 2.16 B |  Canada |
 |
Autolus Therapeutics plc
AUTL
|
9.57 | $ 1.41 | -0.35 % | $ 375 M | Britain |
 |
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | USA |
 |
Axon Enterprise
AXON
|
29.9 | $ 411.97 | -0.2 % | $ 31.2 B | USA |
 |
Aytu BioScience
AYTU
|
186 | $ 2.65 | -1.12 % | $ 16.6 M | USA |
 |
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
BioCardia
BCDA
|
68.1 K | $ 1.18 | -1.67 % | $ 7.87 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
484 | $ 9.59 | 6.26 % | $ 1.98 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
199 | $ 9.46 | -3.47 % | $ 612 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
245 | $ 56.04 | 0.96 % | $ 10.7 B | USA |
 |
BioXcel Therapeutics
BTAI
|
34.2 K | $ 1.18 | -0.42 % | $ 14.4 M | USA |